References
- Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. New Engl J Med 2008; 358:1160 - 1174
- Speake G, Holloway B, Costello G. Recent developments related to the EGFR as a target for cancer chemotherapy. Curr Opin Pharmacol 2005; 5:343 - 349
- Hynes NE, Lane HA. Errb receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer 2005; 5:341 - 354
- Thomas SM, Grandis JR. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev 2004; 30:255 - 268
- Mateo C, Moreno E, Amour K, Lombardero J, Harris W, Perez R. Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity. Immunotechnology 1997; 3:71 - 78
- Fernandez A, Spitzer E, Perez R, Boehmer FD, Eckert K, Zschiesche W, et al. A new monoclonal antibody for the detection of EGF-R in Western blot and paraffin embedded tissue sections. J Cell Biochem 1992; 49:157 - 165
- Crombet-Ramos T, Rak J, Perez R, Viloria-Petit A. Antiproliferative, antiangiogenic and proapoptotic activity of h-r3: a humanized anti-egfr antibody. Int J Cancer 2002; 101:567 - 575
- Miqueli AD, Blanco R, Garcia B, Badia T, Batista AE, Alonso R, et al. Biological activity in vitro of anti-Epidermal Growth Factor Receptor monoclonal antibodies with different affinities. Hybridoma 2007; 26:423 - 431
- Arteaga ME, Ledón N, Casacó A, Pardo B, García M, Boleda M, et al. Systemic and skin toxicity in Cercopithecus aethiops sabaeus monkeys treated during 26 Weeks with a high intravenous dose of the anti-Epidermal Growth Factor Receptor monoclonal antibody nimotuzumab. Cancer Biol Ther 2007; 6:1390 - 1395
- 2007 Available at http://www.emea.europa.eu/humandocs/PDFs/EPAR/erbitux/089404en6.pdf
- Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, et al. Use of the humanized anti-Epidermal Growth Factor Receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004; 22:1646 - 1654
- Allan D. Nimotuzumab: Evidence of clinical benefit without rash. Oncologist 2005; 10:760 - 761
- Shockley TR, Lin K, Sung C, Nagy JA, Tompkins RG, Dedrick RL, et al. A quantitative analysis of tumor specific monoclonal antibody uptake by human melanoma xenografts: Effects of antibody immunological properties and tumor antigen expression levels. Cancer Res 1992; 52:357 - 366
- Tikhomirov IA, Hidalgo GG, Yang E, Sherman I, Rodriguez RP. Bivalent binding properties of Epidermal Growth Factor Receptor (EGFR) targeted monoclonal antibodies: factors contributing to differences in observed clinical profiles 2008. AACR Meeting on Cancer Clinical Trials and Personalized Medicine
- Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006; 55:657 - 670
- Cohenuram M, Saif MW. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anti-Cancer Drug 2007; 18:7 - 15
- Vanhoefer U, Tewes M, Rojo F, Dirsch O, Schleucher N, Rosen O, et al. J Phase I study of the humanized anti-epidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 2004; 22:175 - 184
- Saif MW, Kim R. Incidence and management of cutaneous toxicities associated with cetuximab. Expert Opin Drug Saf 2007; 6:175 - 182
- Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus Cetuximab for squamous—cell carcinoma of the head and neck. New Engl J Med 2006; 354:567 - 578